Last thing I heard Matscum was pimping MEIP. I can't complain about the market eventhough the biotech sector is showing some weakness. As far as ATRS, the TEVA/Mylan saga has really screwed up the momentum.
I wonder why analysts have a loss for the qtr if the epi-pen order was actually big? As far as milestones its probably in the $1 or $2 million range.
"It feels very good to be long ATRS now" - Explain why it feels so good to be long ATRS?
ATRS is losing money everyday with the current pipeline. ATRS will still lose money everyday even if Sumatriptan is approved.
What does that leave you? Hope & a prayer for the epi-pen since ATRS probably won't see a dollar from QST for over 2 yrs.
Thanks for telling me that now I know your TD. What a joke, you've mislead investors any number of times with false information. I give my opinion & admit that I could be wrong however my views have been more accurate then anything else I've seen on the board.
Teva’s unsolicited $40 billion bid for the drug maker Mylan and Mylan’s own unsolicited offer for the rival Perrigo are sweet revenge for the United States taxpayer.
The reason is their flight from the United States in tax inversions has made both more exposed to hostile takeovers. Their executives may now rue the day they left the United States simply to save a few dollars in taxes.
Google headlines for full article, pretty interesting.
"With positive results from the 3,4 Dap study, Jacobus Pharma will be able to submit the drug to the U.S. Food and Drug Administration for approval, says Dr. Donald Sanders of Duke University, the study's lead investigator. "
Everything you've said points to CPRX flying through the approval process but the above statement wouldn't give me a good feeling if I was a shareholder.
I don't have any information about timelines & have no doubt CPRX has a better data set but if Jacob's can file first then it might be good enough. Just because a company gets "Breakthrough" status doesn't necessarily mean they get priority review status also.
5K share buy by a director is not even worth mentioning.
The LEM's community supports Jacobs & they probably did everything possible to help them complete their Phase III before CPRX. CPRX had to do a 3 month run-in before they could conduct the withdrawal portion of the trial whereas Jacob's trial participants didn't need the 3 month run-in since they were already on drug.
I think there is a good chance Jacob's has filed or will file before CPRX. The breakthrough designation will not save CPRX.
You are 100% wrong. Jacob's could already have filed for approval. If Jacob's never filed for Breakthrough designation then CPRX would have been granted it no matter the timing.
Jacob's didn't have to do a 3 month run-in treatment period which would have let them jump ahead of CPRX.
Funds report their holding 45 days from the end of the qtr which means August unless someone acquires more then a 5% position in a company.
The 4.65 million shares have already been placed. The underwriters were allocated another 697,500 shares @ $6.50 that they can sell into the market within the next 30 days & that is what's going on now. If the volume is high enough & the price remains above $6.50 then they can quickly sell those 697K shares & the secondary will close.
There are any number of reasons to raise cash at this point but it gives the company flexibility to speed up the pipeline development. Don't look at the cash raise as a bad thing. They sold less then 5 million shares & the company still has a small share count.
The next cash raise will be at $15.
You actually have to take LPCN's drug twice a day but they're working on a once a day pill. I'm sure most ATRS investors would rather inject themselves once a week then take 14 pills.
LPCN also has another program in development for prevention of recurrent preterm birth which could be a valuable asset.
Biotech Bubble - You used to be able to find companies with promising early stage pipelines at decent values but now every company is worth a billion or two.